Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.63 |
| ▸ | S100A10 | P60903 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 12/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 12/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303721 | 0.96 | ANXA2 (0.61) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4291470 | 0.95 | KDM4E (0.59) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4303145 | 0.95 | RXFP1 (0.60) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL3813910 | 0.93 | KDM4E (0.71) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL3812274 | 0.92 | RXFP1 (0.55) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4299314 | 0.90 | TP53 (0.54) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4291673 | 0.90 | CYP1A2 (0.73) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4291248 | 0.89 | KDM4E (0.62) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4305606 | 0.88 | TP53 (0.53) | RXFP1ANXA2S100A10KDM4EMEN1 | |
| SCHEMBL4299500 | 0.88 | KDM4E (0.57) | RXFP1ANXA2S100A10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | claimed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | claimed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | RXFP1 1183/4885ANXA2 4727/4885S100A10 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.